Search

Your search keyword '"Thymoglobulin"' showing total 1,902 results
Start Over Descriptor "Thymoglobulin"
1,902 results on '"Thymoglobulin"'

4. Diabetes Islet Preservation Immune Treatment (DIPIT)

Author

Diabetes Research Institute Foundation and Camillo Ricordi and Jay Skyler, Professors, University of Miami Miller School of Medicine and Director/Deputy Director, Diabetes Research Institute

Published
2024

9. A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) (TransIT)

Author

Center for International Blood and Marrow Transplant Research, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), North American Pediatric Aplastic Anemia Consortium, Pediatric Transplantation and Cellular Therapy Consortium, Blood and Marrow Transplant Clinical Trials Network, and David Williams, Chief - Division of Hematology/Oncology

Published
2024

33. Immunosuppressive Induction Therapy Using the Antithymocyteglobulin Grafalon: A Single-Center Non-Interventional Study.

Author

Becker, Nikolaus, Pereyra, David, Dingfelder, Jule, Tortopis, Chiara, Saffarian Zadeh, Tina, Riha, Moriz, Kacar, Sertac, Soliman, Thomas, Berlakovich, Gabriela A., and Györi, Georg

Subjects
*BACTERIAL diseases, *LIVER transplantation, *LEUCOPENIA, *OVERALL survival, *BACTEREMIA
Abstract

Background: Induction therapy with depleting antibodies in the setting of liver transplantation (LT) is discussed controversially to this day. The rabbit antithymocyteglobulin (ATG) Thymoglobulin (rATG) was introduced as early as 1984 and was frequently used as a standard regime for induction therapy after LT. There are no public reports characterizing Grafalon (ATG-F), a novel ATG, as an induction agent after LT. Objectives: The aim of this observational non-interventional study was to investigate the safety and efficacy of Grafalon induction therapy and characterize its clinical effects in the setting of LT. Methods: A cohort of 80 patients undergoing deceased donor LT at the Medical University of Vienna and receiving Grafalon as part of the clinical standard immunosuppressive regimen was prospectively included between March 2021 and November 2022. Patients were monitored closely for leukocytopenia and thrombocytopenia during the first postoperative week and followed up for incidence and severity of biopsy-proven acute rejection (BPAR), overall survival, and bacterial infections in the first year after LT. Results: The incidences of thrombocytopenia and leukocytopenia following Grafalon treatment peaked on postoperative day four, with 64% and 31%, respectively. However, there were no cases of severe leukocytopenia after the first postoperative week. Induction therapy with Grafalon resulted in a rate of localized bacterial infections and bacteremia of 28% and 21%, respectively. The rate of BPAR was 12.5% in the first year after LT; the one-year survival rate in this cohort was 90%. Conclusions: Overall, this study provides evidence of the safety and efficacy of Grafalon as an induction agent. Further studies investigating the potential long-term effects of Grafalon, as well as comparison studies with different immunosuppressive regimens, are needed in order to draw further conclusions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Preemptive Therapy of GVHD

Author

University of Alberta, Alberta Health services, and Jan Storek, Professor of Medicine

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results